Though UPS did not disclose the financial details of the deal, the acquisition is expected to be completed by the end of 2023.

In the manufacturing of medical devices, there’s no margin of error. Does it make sense, then, to outsource production of those vital yet sensitive instruments?

Congress is finally acting to address the severe shortage of critical pharmaceutical drugs, a crisis long in the making that was laid bare by the COVID-19 pandemic.

While rates of HIV have been declining, other sexually transmitted diseases have become more prevalent in recent years.

The Medical Supply Chain Resiliency Act would allow the establishment of trusted trade partnerships to diversify the sourcing and procurement of medical devices as well as pharmaceuticals.

Medical supply chains are experiencing a "severe" shortage of cancer drugs after carboplatin and cisplatin were reportedly found to be in “extremely short supply.”

Supply chain resilience has become top of mind for medical professionals and device manufacturers.

The pharmaceutical sector has come under ever-greater scrutiny in recent years, as more and more counterfeit products infiltrate legitimate supply chains.

Life sciences companies need to draw on the tools and protections in their supplier contracts to maintain continuity and minimize disruption.